The ECOG performance status is a validated fundamental predictor of palliative survival and treatment toxicity tolerance in neuro-oncology.
Functional Sentinel Probe
Select the patient's current level of daily physical activity and self-care capability to determine their ECOG performance status and oncological treatment fitness.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Baseline assessment of patients presenting with intracranial or spinal tumors.
Determining eligibility for clinical trials and aggressive adjuvant therapies (chemo/radiation).
Section 2
Pearls/Pitfalls
Surgical Decision Making
In high-grade gliomas, preoperative ECOG status is one of the strongest independent predictors of overall survival. A poor ECOG score (3 or 4) often shifts the treatment paradigm toward palliative care or simple biopsy, rather than gross total resection.
Conversion to Karnofsky Performance Status (KPS)
ECOG 0 ≈ KPS 90-100
ECOG 1 ≈ KPS 70-80
ECOG 2 ≈ KPS 50-60
ECOG 3 ≈ KPS 30-40
ECOG 4 ≈ KPS 10-20
Section 3
Evidence Appraisal
Primary Reference
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken MM et al. • Am J Clin Oncol. 1982;5(6):649-55
Last Comprehensive Review: 2026
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Clinical Utility
Standardized measurement of how a malignancy impacts a patient's daily living abilities.
Determination of eligibility for systemic anticancer therapies (chemotherapy, immunotherapy).
Primary inclusion/exclusion criterion for oncologic clinical trials.
Independent prognostic indicator for patients with advanced malignancy.
Assessment Requirements
PS should be assessed at every clinical encounter, as changes often precede radiographic evidence of disease progression or treatment toxicity.
Grade 2: Capable of self-care; up >50% of waking hours; unable to work.
Grade 3: Limited self-care; confined to bed/chair >50% of waking hours.
Grade 4: Completely disabled; totally confined.
Grade 5: Dead.
Karnofsky Performance Status (KPS) Mapping
ECOG
KPS %
Clinical Descriptor
0
100–90
Normal activity; no evidence of disease.
1
80–70
Normal activity with effort; cares for self.
2
60–50
Requires occasional assistance; ambulatory.
3
40–30
Disabled; requires special care and assistance.
4
20–10
Very ill; hospitalization necessary; moribund.
5
0
Dead.
Section 3
Pearls/Pitfalls
Inter-Rater Reliability
Azam et al. (2019) demonstrated high inter-rater reliability across consultants, registrars, and specialist nurses.
The "Nurse Factor": Oncology nurses often provide more conservative (poorer) PS ratings than physicians because they are typically more aware of a patient’s actual social situation and level of dependence.
Scenario Complexity: PS 2 and PS 3 represent the highest degree of variability, particularly when comorbidities (e.g., Rheumatoid Arthritis) or cognitive impairments are present.
The ECOG 2 Pivot
ECOG 2 is often the "threshold" for treatment. Patients at this level have significantly higher risks of chemotherapy toxicity compared to ECOG 0-1, yet are still frequently considered for therapy.
Section 4
Next Steps
Treatment Triage
ECOG 0–1: Usually fit for standard systemic therapy and clinical trials.
ECOG 2: High risk for toxicity; consider dose reductions or single-agent therapy.
ECOG 3–4: In advanced malignancy, risks of systemic treatment often outweigh benefits; Best Supportive Care (BSC) is frequently the most appropriate path.
Section 5
Evidence Appraisal
Primary Scale Definition
Toxicity and response criteria of the Eastern Cooperative Oncology Group.
Oken MM et al. • Am J Clin Oncol. 1982;Established the standardized 0-5 criteria.
Inter-rater Validation
Performance Status Assessment by Using ECOG Score for Cancer Patients.
Azam F et al. • Case Rep Oncol. 2019;Found no significant variation in PS assessment across different oncology HCP groups.
Section 6
Literature
Historical Context
Key elements of the ECOG scale first appeared in 1960 (Zubrod et al.). It was developed by the Eastern Cooperative Oncology Group (now ECOG-ACRIN) to ensure consistency in measuring disease impact across multiple participating hospitals.
